Drug Profile
Research programme: cyclodextrin-based therapeutics for cardiovascular conditions - Alveron Pharma
Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Okklo Life Sciences; Sanquin Blood Supply Foundation
- Developer Alveron Pharma
- Class Cyclodextrins
- Mechanism of Action Blood coagulation factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Blood coagulation disorders
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Blood-coagulation-disorders(Prevention) in Netherlands
- 11 Aug 2021 Cyclodextrin-based therapeutics are still in preclinical trials for coagulation disorders (Prevention) in Netherlands (Alveron Pharma website, August 2021)
- 30 Jul 2021 Cyclodextrin-based therapeutics are still in preclinical trials for Blood coagulation disorders in Netherland (Alveron Pharma website, July 2021)